The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease
After being informed of the study and potential risks and benefits, patients meeting
eligibility requirements will be randomized to receive oral N-acetylcysteine (NAC) as
follows:
Inpatients:
- N-acetylcystine (NAC) 25 mg/kg PO (rounded up to the nearest 600 mg) q4hrs until
discharge
- N-acetylcysteine (NAC) 1200 mg PO BID x 1 week post-discharge
Outpatients:
- N-acetylcysteine (NAC) 2400 mg PO x 1 then 1200 mg PO BID x 2 weeks
Drug: N-acetylcysteine
Oral formulation: 600 mg capsules of N-acetylcysteine
Other Name: NAC, acetylcysteine, N-acetyl-L-cysteine, NALC
Inclusion Criteria:
- known or suspect COVID-19 disease AND one or more of the following influenza-like
symptoms, including: diarrhea vomiting fever (subjective or measured) chills myalgias
fatigue sore throat headache cough nasal/sinus congestion or rhinorrhea shortness of
breath chest pain
Exclusion Criteria:
- Minors, pregnant women and people unable to provide informed consent are excluded from
this study
CHA Cambridge Hospital
Cambridge, Massachusetts, United States
CHA Everett Hospital
Everett, Massachusetts, United States
CHA Respiratory Clinic
Somerville, Massachusetts, United States
CHA Somerville campus
Somerville, Massachusetts, United States